Drug Approval | March 21, 2022
USFDA approves Perrigo’s Nasonex
Nasonex is a registered trademark of Organon and is used by Perrigo and its affiliates under license
Nasonex is a registered trademark of Organon and is used by Perrigo and its affiliates under license
At the interim analysis, the combination of Keytruda and Lynparza did not demonstrate a benefit in overall survival (OS), one of the study’s dual primary endpoints, compared to the control arm of either abiraterone acetate or enzalutamide
This pre-packaged release is a ready-to-go solution with powerful, straightforward bioanalysis pipeline support
Guardant360 CDx is a comprehensive genomic profiling test that utilizes blood samples from patients with advanced solid cancers
The award recognizes and supports promising women scientists
Lynparza is approved in the US, EU, Japan and several other countries for the treatment of patients with gBRCAm, HER2-negative, metastatic breast cancer previously treated with chemotherapy based on results from the OlympiAD Phase III trial
Tislelizumab is now approved for seven indications in China
Experts will speak about primary tumours of the nervous system and also the tumours of other body parts which get metastasized to the nervous system
New results build on previously reported significant recurrence-free survival (rfs) benefit seen in these patients
Toyobo will start looking at ways to use the knowhow from DMC’s sophisticated fermentation process technologies to enhance the efficiency of making its bioproducts
Subscribe To Our Newsletter & Stay Updated
